SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification

Rhea-AI Summary

SciSparc Ltd. (Nasdaq: SPRC), a clinical-stage pharmaceutical company focused on central nervous system disorders and rare diseases, has successfully regained compliance with Nasdaq's minimum bid price requirement. The company received official notification from Nasdaq on July 18, 2025, confirming that its shares maintained a closing bid price of $1.00 or higher for 10 consecutive business days, satisfying Listing Rule 5550(a)(2).

With this achievement, Nasdaq has closed the previous bid price deficiency matter, marking an important milestone for SciSparc's continued listing on the exchange.

Positive

• Regained Nasdaq listing compliance, removing delisting risk
• Maintained share price above $1.00 for 10 consecutive trading days
• Resolved previous bid price deficiency matter with Nasdaq

Negative

• Previous trading below minimum bid price requirement indicates historical stock price weakness

News Market Reaction

+2.50%

1 alert

+2.50% News Effect

On the day this news was published, SPRC gained 2.50%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Tel Aviv, July 22, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (“SciSparc” or the “Company”) (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, reported the receipt on July 18, 2025 of a written notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained compliance with Listing Rule 5550(a)(2), which requires the Company’s ordinary shares to maintain a minimum bid price of $1.00 per share.

The Nasdaq staff made this determination of compliance after the closing bid price of the Company’s ordinary shares was at $1.00 per share or greater for 10 consecutive business days. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and Nasdaq considers the prior bid price deficiency matter now closed.

About SciSparc Ltd. (Nasdaq: SPRC):

SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; and SCI-210 for the treatment of autism and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds’ oil-based products on the Amazon.com Marketplace.

Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055

FAQ

Has SciSparc (SPRC) regained Nasdaq compliance in 2025?

Yes, SciSparc received confirmation from Nasdaq on July 18, 2025 that it has regained compliance with the minimum bid price requirement by maintaining a closing bid price of $1.00 or higher for 10 consecutive business days.

What is the minimum bid price requirement for Nasdaq listing that SPRC had to meet?

According to Nasdaq Listing Rule 5550(a)(2), companies must maintain a minimum bid price of $1.00 per share to remain compliant.

What does SciSparc's Nasdaq compliance mean for investors?

The compliance means SciSparc has resolved its listing deficiency and removed the risk of delisting from Nasdaq, providing more stability for investors regarding the stock's exchange listing status.

What is SciSparc's main business focus?

SciSparc is a specialty clinical-stage pharmaceutical company that develops therapies to treat disorders and rare diseases of the central nervous system.